AR049395A1 - Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion, y las composiciones farmaceuticas que las contienen - Google Patents

Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion, y las composiciones farmaceuticas que las contienen

Info

Publication number
AR049395A1
AR049395A1 ARP050102423A ARP050102423A AR049395A1 AR 049395 A1 AR049395 A1 AR 049395A1 AR P050102423 A ARP050102423 A AR P050102423A AR P050102423 A ARP050102423 A AR P050102423A AR 049395 A1 AR049395 A1 AR 049395A1
Authority
AR
Argentina
Prior art keywords
expressed
rays
strontium ranelate
degrees
pharmaceutical compositions
Prior art date
Application number
ARP050102423A
Other languages
English (en)
Inventor
Stephane Horvath
Isabelle Demuynck
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049395(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR049395A1 publication Critical patent/AR049395A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Steroid Compounds (AREA)

Abstract

Reivindicacion 1: Forma alfa cristalina de ranelato de estroncio de formula (1): caracteriada por un contenido de agua de desde 22 a 24% y por el siguiente diagrama de difraccion de rayos X de polvo medido usando un difractometro PANalytical X'Pert Pro junto con un detector X'Celerator y expresado en términos de posicion de los rayos (ángulo de Bragg 2 theta, expresado en grados), altura de los rayos (expresada en conteos), área de los rayos (expresada en conteos x grados), anchura de los rayos a media altura ("FWHM", expresada en grados) y distancia interplanar d (expresada en amstrongs): (copiar tabla de pag.12).
ARP050102423A 2004-09-30 2005-06-14 Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion, y las composiciones farmaceuticas que las contienen AR049395A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410335A FR2875807B1 (fr) 2004-09-30 2004-09-30 Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
AR049395A1 true AR049395A1 (es) 2006-07-26

Family

ID=34942420

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102423A AR049395A1 (es) 2004-09-30 2005-06-14 Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion, y las composiciones farmaceuticas que las contienen

Country Status (42)

Country Link
US (2) US7459568B2 (es)
EP (2) EP1944302A1 (es)
JP (2) JP2006104184A (es)
KR (1) KR100816590B1 (es)
CN (1) CN100391956C (es)
AP (1) AP1930A (es)
AR (1) AR049395A1 (es)
AT (1) ATE411308T1 (es)
AU (1) AU2005202718B2 (es)
BR (1) BRPI0502228A (es)
CA (1) CA2508824C (es)
CO (1) CO5710195A1 (es)
CR (1) CR7876A (es)
CY (1) CY1108797T1 (es)
DE (1) DE602005010359D1 (es)
DK (1) DK1642897T3 (es)
EA (1) EA008474B1 (es)
EC (1) ECSP055859A (es)
ES (1) ES2314593T3 (es)
FR (1) FR2875807B1 (es)
GE (1) GEP20074106B (es)
GT (1) GT200500130A (es)
HK (1) HK1086260A1 (es)
HR (1) HRP20080652T3 (es)
IL (1) IL169237A (es)
MA (1) MA27815A1 (es)
MX (1) MXPA05006407A (es)
NO (1) NO333948B1 (es)
NZ (1) NZ540802A (es)
OA (1) OA13013A (es)
PA (1) PA8638201A1 (es)
PE (1) PE20060364A1 (es)
PL (1) PL1642897T3 (es)
PT (1) PT1642897E (es)
RS (1) RS51110B (es)
SA (1) SA05260168B1 (es)
SG (1) SG121035A1 (es)
SI (1) SI1642897T1 (es)
TW (1) TWI367881B (es)
UA (1) UA80008C2 (es)
WO (1) WO2006035122A1 (es)
ZA (1) ZA200504937B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101206208B (zh) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 一种用hplc法分析雷尼酸锶原料及其制剂的方法
EP2346846A1 (en) 2008-09-29 2011-07-27 Ratiopharm GmbH Anhydrate and hydrate forms of strontium ranelate
IT1398542B1 (it) 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
US9301945B2 (en) 2011-07-21 2016-04-05 Emory University Methods for treating inflammatory conditions and states, and cancers by antagonizing NF-κB activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) * 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en) 2012-03-23 2013-09-25 Urquima S.A. Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
IL161164A0 (en) * 2001-10-03 2004-08-31 Teva Pharma Preparation of levofloxacin and forms thereof
EP2272501B1 (en) * 2002-01-09 2013-03-20 Emisphere Technologies, Inc. Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
JP2006508909A (ja) * 2002-08-06 2006-03-16 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの新規な結晶形
FR2844797B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844796A1 (fr) * 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
KR20060049966A (ko) 2006-05-19
BRPI0502228A (pt) 2006-05-09
EP1642897B9 (fr) 2009-08-12
JP2006104184A (ja) 2006-04-20
HK1086260A1 (en) 2006-09-15
EP1642897B1 (fr) 2008-10-15
GEP20074106B (en) 2007-05-10
ECSP055859A (es) 2006-09-18
US7459568B2 (en) 2008-12-02
WO2006035122A1 (fr) 2006-04-06
ZA200504937B (en) 2006-04-26
TWI367881B (en) 2012-07-11
AU2005202718A1 (en) 2006-04-13
CY1108797T1 (el) 2014-04-09
MA27815A1 (fr) 2006-04-03
DK1642897T3 (da) 2009-01-26
ES2314593T3 (es) 2009-03-16
GT200500130A (es) 2005-12-20
FR2875807A1 (fr) 2006-03-31
RS51110B (sr) 2010-10-31
IL169237A (en) 2010-12-30
JP2010132669A (ja) 2010-06-17
CR7876A (es) 2007-12-10
PA8638201A1 (es) 2006-05-16
US7745482B2 (en) 2010-06-29
NO20052998L (no) 2006-03-31
DE602005010359D1 (de) 2008-11-27
OA13013A (fr) 2006-11-10
AU2005202718B2 (en) 2010-09-16
NZ540802A (en) 2006-11-30
HRP20080652T3 (en) 2009-01-31
SI1642897T1 (sl) 2009-02-28
TW200610758A (en) 2006-04-01
US20080312314A1 (en) 2008-12-18
CA2508824A1 (fr) 2006-03-30
CN1754878A (zh) 2006-04-05
CN100391956C (zh) 2008-06-04
PT1642897E (pt) 2008-11-27
FR2875807B1 (fr) 2006-11-17
US20060069271A1 (en) 2006-03-30
PE20060364A1 (es) 2006-06-17
SG121035A1 (en) 2006-04-26
CO5710195A1 (es) 2006-12-29
SA05260168B1 (ar) 2009-02-25
NO333948B1 (no) 2013-10-28
PL1642897T3 (pl) 2009-04-30
EA008474B1 (ru) 2007-06-29
ATE411308T1 (de) 2008-10-15
EP1642897A1 (fr) 2006-04-05
EA200500842A1 (ru) 2006-04-28
NO20052998D0 (no) 2005-06-17
AP1930A (en) 2008-12-15
UA80008C2 (uk) 2007-08-10
EP1944302A1 (fr) 2008-07-16
CA2508824C (fr) 2009-03-24
AP2005003323A0 (en) 2005-06-30
MXPA05006407A (es) 2006-04-05
KR100816590B1 (ko) 2008-03-24

Similar Documents

Publication Publication Date Title
AR049395A1 (es) Forma cristalina alfa de ranelato de estroncio, su procedimiento de preparacion, y las composiciones farmaceuticas que las contienen
AR056573A1 (es) Forma cristalina delta del clohidrato de ivabradina,un procedimiento para su preparacion,composiciones farmaceuticas que la contienen y usos en trastornos cardiovasculares.
AR052926A1 (es) Forma cristalina gama del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones que la contienen
RS51943B (en) PIPERIDINSKI GPCR AGONIST
EA200300107A1 (ru) Кристаллические формы трет-бутиламиновой соли периндоприла
BRPI0719395C1 (pt) tablete revestido de filme
HRP20170540T1 (hr) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
TW200744588A (en) Pharmaceutical composition for external use
EA200601274A1 (ru) Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат
RS50600B (sr) Kristalni oblik gama - d ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
ME01992B (me) Jedinjenje diarilhidantoina
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
RS50599B (sr) KRISTALNI OBLIK BETA-d IVABRADIN HLORHIDRATA, POSTUPAK NJEGOVE IZRADE I FARMACEUTSKE SMEŠE KOJE GA SADRŽE
EA200300103A1 (ru) НОВАЯ β КРИСТАЛЛИЧЕСКАЯ ФОРМА ТРЕТ-БУТИЛАМИНОВОЙ СОЛИ ПЕРИНДОПРИЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
NO20062098L (no) Faststofftilstandmontelukast
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
WO2008084786A1 (ja) 化合物及び感放射線性組成物
BRPI0617180B8 (pt) processo para produção de uma mistura diretamente comprimível, formulação de ibuprofeno produzida pelo processo, e, forma de dosagem farmacêutica
UA97638C2 (ru) Способ синтеза ранелата стронция и его гидратов
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
CU23927B1 (es) Sal de difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamoilmetil)piperidin-4-il]oxi}quinazolina
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
BRPI0407519A (pt) derivados de benzofurano

Legal Events

Date Code Title Description
FC Refusal